Adicet Bio Inc. Common Stock (ACET)

About ACET

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edite…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

102

Website

www.adicetbio.com/

Fundamentals

1-day range

$8.76$9.25

Market cap

$86.38M

P/E (trailing)

—

P/E (forward)

-2.29

EPS (trailing)

$-13.02

Dividend yield

—

Beta

1.63

Avg. volume

90.5K

Dividend pay date

September 16, 2020

Forecasts

6 analyst ratings

Adicet Bio Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ACET

  Adicet Bio Inc. Common Stock

  $9.05

  ▲ 0.44%
  Market cap $86.38MP/E —
  $6.01$17.44
• NTHI

  NeOnc Technologies Holdings Inc. Common Stock

  $4.69

  ▲ 1.74%
  Market cap $89.73MP/E —
  $3.01$12.99
• LFVN

  Lifevantage Corporation Common Stock (Delaware)

  $6.6

  ▲ 2.33%
  Market cap $83.01MP/E 14.23
  $3.9$14.28
• VRCA

  Verrica Pharmaceuticals Inc. Common Stock

  $5.54

  ▲ 9.27%
  Market cap $90.19MP/E —
  $3.28$9.82
• NMAD

  Nomad Power Solutions Inc. Common Stock

  $4.33

  ▼ 2.04%
  Market cap $81.57MP/E —
  $3.12$7.7
• FBIO

  Fortress Biotech Inc. Common Stock

  $2.77

  ▼ 1.07%
  Market cap $91.68MP/E 0.75
  $2.18$4.53
• ATHE

  Alterity Therapeutics Limited American Depositary Shares

  $4.51

  ▼ 1.10%
  Market cap $80.78MP/E —
  $0.01$0.785

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Adicet Bio Reveals FDA Clearance Of IND Application For ADI-212; Co Plans To Initiate Phase 1 Enrollment In Patients With mCRPC In Q4 Of 2026
  benzinga · 8/27/2026
• Adicet Bio Reveals FDA Clearance Of IND Application For ADI-212; Co Plans To Initiate Phase 1 Enrollment In Patients With mCRPC In Q4 Of 2026
  Benzinga · 8/27/2026
• Adicet Bio: A Cheap Gamma Delta T-Cell Play
  SeekingAlpha · 8/14/2026
• Guggenheim Maintains Buy on Adicet Bio, Lowers Price Target to $90
  Benzinga · 8/6/2026
• Adicet Bio Q2 EPS $(1.99) Beats $(2.03) Estimate
  Benzinga · 8/5/2026

• Lloyd Klickstein · August 5, 2026 · Grant

  18.3K
• Katie Peng · June 21, 2026 · Grant

  4.2K
• Lloyd Klickstein · June 21, 2026 · Grant

  4.2K
• Andrew Sinclair · June 21, 2026 · Grant

  4.2K
• Michael Grissinger · June 21, 2026 · Grant

  4.2K
• Jeffrey Chodakewitz · June 21, 2026 · Grant

  4.2K
• Steve Dubin · June 21, 2026 · Grant

  4.2K
• Blake Aftab · June 19, 2026 · Grant

  55.0K
• Chen Schor · June 19, 2026 · Grant

  55.0K
• RA Capital Healthcare Fund LP · April 27, 2026 · J

  250.0K
• ORBIMED ADVISORS LLC · April 8, 2026 · Sale

  40.4K @ $6.52
• ORBIMED ADVISORS LLC · April 8, 2026 · Sale

  32.5K @ $6.29
• ORBIMED ADVISORS LLC · April 7, 2026 · Sale

  2.4K @ $6.38
• ORBIMED ADVISORS LLC · April 7, 2026 · Sale

  29.3K @ $6.53
• Maltzman Julia D. · March 25, 2026 · Grant

  72.6K

Institutional Ownership

March 31, 2026

Total shares held

6.34M

Total value held

$42.38M

Institutional holders

45